Phenylephrine “Not Significantly Different From” Placebo – Schering Study
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough released a study on phenylephrine's efficacy as compared to pseudoephedrine and placebo Oct. 31 that "raises even more questions" about the drug, according to Rep. Henry Waxman (D-Calif.)
You may also be interested in...
Data Support Phenylephrine Efficacy, But More Studies Needed – NDAC
FDA's Nonprescription Drugs Advisory Committee recommends additional studies on phenylephrine efficacy for treatment of nasal congestion, although members say current data support the efficacy of the OTC cough/cold ingredient
Citizen Petition On Phenylephrine Requests Pulling OTC Status For Children
A citizen petition asks FDA to withdraw OTC approval for phenylephrine use by children under 12 years old and to raise the maximum dose to 25 mg, but also recommends more research to determine the most effective dosage level
Democrats Expected To Put Supplement, Drug Regulation Under Microscope
Increased scrutiny of issues including the safety of dietary supplements and phenylephrine efficacy is likely as senior Democrats move into leadership roles on Congressional committees following the 2006 midterm elections